The Case FOR CagriSema: Why the Cagrilintide + Semaglutide Stack Shows Genuine Promise

Of all the combination strategies currently studied in obesity pharmacology, the cagrilintide-plus-semaglutide pairing — branded CagriSema by Novo Nordisk — stands out as one of the few where a fixed-dose combination has been taken all the way through Phase 3 trials in tens of thousands of subjects. The mechanistic rationale is strong, the clinical signal is substantial, and the data that have emerged from the REDEFINE program are among the most compelling in the GLP-1 space to date.

Two Distinct Mechanisms, One Complementary Goal

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, suppresses glucagon, stimulates insulin secretion in a glucose-dependent manner, and acts centrally on hypothalamic circuits governing appetite and satiety. These effects are well-characterised across the Ozempic and Wegovy trial programs.

Cagrilintide works through a different receptor entirely. It is a long-acting analogue of amylin, a peptide co-secreted with insulin from pancreatic beta cells. Amylin receptors are expressed in the area postrema and nucleus tractus solitarius — brainstem regions that process meal-related satiety signals. Amylin acts to reduce meal size, slow gastric emptying through a vagal mechanism, and suppress post-meal glucagon. Critically, amylin and GLP-1 operate on partially non-overlapping neural circuits, which is the core rationale for combining them: each pathway delivers a satiety signal, but the signals converge from different directions.

Preclinical rodent work published prior to human trials showed that co-administration of amylin analogues with GLP-1 receptor agonists produced additive to synergistic reductions in food intake and body weight compared with either compound alone — a finding that motivated the clinical program.

Phase 2 Evidence Set the Stage

A Phase 2 randomised trial, published in The Lancet in 2023, enrolled adults with type 2 diabetes and evaluated once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg over 32 weeks. The combination arm achieved approximately 15.6% body weight reduction, outperforming either monotherapy arm. The dose-response pattern was consistent and the safety profile did not reveal new signals beyond those already established for semaglutide alone.

This Phase 2 result was sufficient to advance CagriSema into the REDEFINE Phase 3 program.

REDEFINE Phase 3: A 20% Weight Loss Signal

REDEFINE 1, the pivotal trial in adults with obesity but without type 2 diabetes, enrolled approximately 3,400 participants and ran for 68 weeks. Participants in the CagriSema arm lost a mean of 20.4% of body weight, compared with 14.9% for semaglutide alone and 11.5% for cagrilintide alone. Sixty percent of CagriSema participants achieved at least 20% weight loss; 23% lost 30% or more of their starting body weight.

REDEFINE 2, which enrolled approximately 1,200 adults with type 2 diabetes, showed a mean weight reduction of 13.7% in the CagriSema group versus 3.4% with placebo, alongside substantial HbA1c improvements — 73.5% of the combination group achieved an HbA1c of 6.5% or below by week 68.

These effect sizes represent the largest weight loss outcomes reported in any Phase 3 obesity pharmacotherapy trial to date. They are particularly notable because they were achieved with once-weekly subcutaneous injections of a fixed-dose combination.

The Synergy Is Mechanistically Coherent

The weight loss advantage of CagriSema over semaglutide monotherapy — roughly 5 to 6 additional percentage points of body weight — aligns with what would be predicted from the complementary receptor pharmacology. GLP-1 acts predominantly in the hypothalamus and peripheral gut; amylin acts predominantly in the brainstem. The two pathways reinforce satiety signals at multiple levels of the central nervous system without the receptor competition or tachyphylaxis risks that would come from stacking two compounds hitting the same receptor.

Regulatory Pathway

Novo Nordisk submitted a New Drug Application to the FDA for CagriSema in 2025, with regulatory review expected to conclude in 2026. This is not a research-community stack assembled from individual components — it is a pharmaceutical-grade fixed-dose combination with a defined NDA package and a Phase 3 safety database of thousands of participants. The evidence base supporting the combination is unusually robust for this class of compound.

---

CagriSema (cagrilintide + semaglutide) is an investigational compound under FDA review as of 2026. It is not approved for human use. This article discusses published clinical trial data for research and educational purposes only. Nothing here constitutes medical advice. Do not use any research compound without the guidance of a qualified healthcare professional.